Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing. He wasn’t expecting a fall during an ice storm to lead to a cancer diagnosis. But ...

About 1 in 5 patients with B-cell lymphoma treated with loncastuximab develop skin-related adverse events, particularly ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...

"Histological transformation of FL to DLBCL was a low‐incidence event associated with distinct clinical features and inferior survivals . . . By population‐based analysis and external validation, ...

A case study details the cytological and histological features of fibrin-assisted diffuse large B-cell lymphoma in a patient with no clinical symptoms, highlighting the diagnostic challenges of this ...

Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL). A study of 32 clinical samples from ...

In the article that accompanies this editorial, Bartlett et al 11 present the results of ECHELON-3, a phase III trial comparing brentuximab vedotin + lenalidomide + rituximab (BV + Len + R) with ...

– Application is based on data from the Phase III STARGLO study where Columvi plus chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival – – This ...

Intravascular large B-cell lymphoma (IVLBCL) is a very rare, aggressive non-Hodgkin’s lymphoma. With IVLBCL, lymphoma cells build up in small blood vessels, which can block blood flow and harm organs.